I. Florea

发表

Teenage perspectives on urban environments. Case studies from contemporary Bucharest

I. Florea, 2010 .

Structural and functional MRI of altered brain development in a novel adolescent rat model of quinpirole-induced compulsive checking behavior

T. Heskes, B. Franke, D. Joel, 2020, European Neuropsychopharmacology.

GASTRITIS AND HELICOBACTER PYLORI IN CHILDREN - PRIMARY AND SECONDARY ENDOSCOPIC DIAGNOSIS

M. Burlea, G. Păduraru, A. Ignat, 2015 .

The safety and tolerability of vortioxetine: Analysis of data from randomized placebo-controlled trials and open-label extension studies

D. Baldwin, G. Nomikos, I. Florea, 2016, Journal of psychopharmacology.

Management of Depression in Adolescents in Japan.

Takuya Saito, I. Florea, E. Reines, 2019, Journal of child and adolescent psychopharmacology.

A Field of Contention: Evidence from Housing Struggles in Bucharest and Budapest

Kerstin Jacobsson, I. Florea, Ágnes Gagyi, 2018 .

Factors associated with failure to achieve remission and with relapse after remission in patients with major depressive disorder in the PERFORM study

J. Haro, B. Rive, M. Knapp, 2017, Neuropsychiatric disease and treatment.

Comparative evaluation of vortioxetine as a switch therapy in patients with major depressive disorder

M. Thase, E. Vieta, N. Danchenko, 2017, European Neuropsychopharmacology.

Effectiveness of Vortioxetine on Emotional Blunting in Patients with Major Depressive Disorder with inadequate response to SSRI/SNRI treatment.

A. Fagiolini, H. Loft, I. Florea, 2020, Journal of affective disorders.

Efficacy of vortioxetine on the physical symptoms of major depressive disorder

D. Baldwin, I. Florea, M. C. Christensen, 2018, Journal of psychopharmacology.

Efficacy of vortioxetine in working patients with generalized anxiety disorder

R. McIntyre, H. Loft, I. Florea, 2017, CNS Spectrums.

Efficacy of Vortioxetine on Cognitive Functioning in Working Patients With Major Depressive Disorder.

R. Lam, R. McIntyre, H. Loft, 2017, The Journal of clinical psychiatry.

Ef fi cacy of vortioxetine in working patients with generalized anxiety disorder

R. McIntyre, H. Loft, I. Florea, 2017 .

A comparative study of the efficacy of acute and continuation treatment with escitalopram versus duloxetine in patients with major depressive disorder

I. Florea, A. Wade, K. Gembert, 2007, Current medical research and opinion.

Patient Expectations and Experiences of Antidepressant Therapy for Major Depressive Disorder: A Qualitative Study

B. Baune, A. Ettrup, Bjarke Ebert, 2021, Neuropsychiatric disease and treatment.

A randomized clinical study of Lu AA21004 in the prevention of relapse in patients with major depressive disorder

J. Boulenger, H. Loft, I. Florea, 2012, Journal of psychopharmacology.

The effect of vortioxetine on overall patient functioning in patients with major depressive disorder

D. Sheehan, B. Rive, H. Loft, 2017, Brain and behavior.

Lu AA21004, a multimodal psychotropic agent, in the prevention of relapse in adult patients with generalized anxiety disorder

D. Baldwin, H. Loft, I. Florea, 2012, International clinical psychopharmacology.

Intravenous vortioxetine to accelerate onset of effect in major depressive disorder: a 7-day randomized, double-blind, placebo-controlled exploratory study

A. Ettrup, I. Florea, C. Baayen, 2020, International clinical psychopharmacology.

Intravenous vortioxetine to accelerate onset of effect in major depressive disorder: a 2-week, randomized, double-blind, placebo-controlled study

E. Vieta, A. Ettrup, I. Florea, 2019, International clinical psychopharmacology.

Cholinergic activity correlates with reserve proxies in Alzheimer's disease

Stefano F. Cappa, Daniela Perani, Marco Tettamanti, 2013, Neurobiology of Aging.

Efficacy of vortioxetine in patients with major depressive disorder reporting childhood or recent trauma.

R. McIntyre, H. Loft, I. Florea, 2019, Journal of affective disorders.

A meta-analysis of the efficacy of vortioxetine in patients with major depressive disorder (MDD) and high levels of anxiety symptoms.

D. Baldwin, G. Nomikos, I. Florea, 2016, Journal of affective disorders.

Prevention of relapse in generalized anxiety disorder by escitalopram treatment.

C. Allgulander, I. Florea, A. Huusom, 2006, The international journal of neuropsychopharmacology.

[11C]-MP4A PET cholinergic measurements in amnestic mild cognitive impairment, probable Alzheimer's disease, and dementia with Lewy bodies: a Bayesian method and voxel-based analysis.

Alessandra Bertoldo, Karl Herholz, Daniela Perani, 2012, Journal of Alzheimer's disease : JAD.

CONTRIBUTIONS TOWARDS ELUCIDATING THE CONCEPT OF „RESTRICTION OF COMPETITION BY OBJECT”

I. Florea, 2018 .

Validation of the Oxford Depression Questionnaire: Sensitivity to change, minimal clinically important difference, and response threshold for the assessment of emotional blunting.

A. Fagiolini, G. Goodwin, H. Loft, 2021, Journal of Affective Disorders.

The effect of vortioxetine on health-related quality of life in patients with major depressive disorder.

B. Rive, H. Loft, N. Danchenko, 2015, Clinical therapeutics.

Vortioxetine 20 mg/day in patients with major depressive disorder: updated analysis of efficacy, safety, and optimal timing of dose adjustment

A. Fagiolini, R. McIntyre, H. Loft, 2021, CNS Spectrums.

A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients

M. Sarchiapone, J. Boulenger, T. Bækdal, 2006, Current medical research and opinion.

Urban struggles and theorising from Eastern European cities

I. Florea, Ana Vilenica, Veda Popovici, 2021 .

Vortioxetine in patients with major depressive disorder and high levels of anxiety symptoms: An updated analysis of efficacy and tolerability.

A. Fagiolini, H. Loft, I. Florea, 2023, Journal of affective disorders.

Vortioxetine (Lu AA21004) in the long-term open-label treatment of major depressive disorder

D. Baldwin, I. Florea, T. Hansen, 2012, Current medical research and opinion.

Effectiveness of long-term vortioxetine treatment of patients with major depressive disorder

E. Vieta, H. Loft, I. Florea, 2017, European Neuropsychopharmacology.

Clinical benefits of vortioxetine 20 mg/day in patients with major depressive disorder

A. Fagiolini, R. McIntyre, H. Loft, 2023, CNS Spectrums.